Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07118579

Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

2 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

About this study

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy, aiming to enhance surgical safety and improve postoperative outcomes in pediatric patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 2-12 years
  • ASA physical status I-II
  • Body mass index (BMI): 14-28 kg/m²
  • Scheduled for elective tonsillectomy with or without adenoidectomy
  • Signed informed consent by legal guardian(s) and assent by children (≥8 years old)

Exclusion criteria

  • History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)
  • Previous episodes of significant PRAEs
  • Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)
  • Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic/renal function
  • Preoperative moderate-to-severe respiratory infections requiring surgery postponement
  • Recent participation in other clinical trials

Treatment and study plan

Remimazolam

Drug

remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)

Other names: Remi

Propofol

Drug

Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)

Other names: PRO

ciprofol

Drug

Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)

Other names: CIP

Primary outcomes

  1. The incidence of perioperative respiratory adverse events

    Time frame: 5days

    The perioperative respiratory adverse events including: laryngospasm, bronchospasm, severe cough, oxygen desaturation, airway obstruction.

Secondary outcomes

  1. Anesthesia duration

    Time frame: 1 day

    From anesthesia induction to discontinuation of anesthetics

  2. Emergence time

    Time frame: 1 day

    From anesthetic discontinuation to eye opening on command

  3. Extubation time

    Time frame: 1 day

    From anesthetic discontinuation to endotracheal tube removal

  4. PACU stay duration

    Time frame: 1 day

    From PACU admission to meeting discharge criteria

  5. The modified Aldrete score

    Time frame: 1 day

    Upon admission to the PACU, the child was assessed using the modified Aldrete score, which ranges from 0 to 10. A higher score indicates a better recovery status.

  6. doses of drugs

    Time frame: 24 hours

    Total sedative/analgesic consumption

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Official study title

Effects of Remimazolam and Ciprofol Total Intravenous Anesthesia on Perioperative Respiratory Adverse Events in Pediatric Tonsillectomy and Adenoidectomy: A Randomized Controlled Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 12, 2025
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.